# Soluble copper salt containing composition useful for forming technetium labelled radiodiagnostic agents.

## Abstract
The present invention relates to compositions for mak ing technetium labelled radiodiagnostic agents and, in par ticular, to soluble copper salt containing compositions for reducing technetium or accelerating the reduction of tech netium for labelling such radiodiagnostic agents, kits for preparing such

## Claims
What is claimed is 1. A composition for preparing technetium complexes for radiodiagnostic imaging, said composition comprising an admixture of a a soluble copper salt and b a target seeking ligand or aqueous salt thereof, having the following structure EMI31.1 wherein i is an integer from 1 to 6 R , R1, R2, R3, R4, R5 and R6 are each independently selected from hydrogen or substituted or unsubstituted alkyl, aryl, alkylaryl, arylalkyl, monocycloalkyl, polycycloalkyl, heterocyclic and carbocyclic groups, and R plus Ri may be taken together to form a cyclic compound or separately to form a linear compound yl, y2, y3, y4, Y5 and Y6 are independently selected from substituted or unsubstituted alkyl, aryl, alkylaryl, arylalkyl, monocycloalkyl, polycycloalkyl, heterocyclic and carbocyclic groups A1, A2, A3, A4, A5 and A6 are each, independently, a neutral donor atoms having a free electron pair available for complexing with Tc 99m or Tc 99 to form a cationic complex and kl, k2, k3, k4, k5 and k6 are each independently zero or onet orEMI32.1 wherein R, R , R and R are independently selected from hydrogen or substituted or usubstituted alkyl, aryl, alkylaryl, arylalkyl, monocylcloalkyl, polycycloalkyl, heterocyclic and carbocyclic groups A, A , A and A are independently selected from the group of neutral donor atoms having a pair of electrons available for complexing with Tc 99m or Tc 99 to form a cationic complex B is an atom selected from the group of neutral donor atoms having a pair of electrons available for complexing with Tc 99m or Tc 99 or from the elements listed in Group IV A of the periodic tablet n, n , n and n are independently the integer 1 or 2 and m is 0 or 1. 2. The composition of Claim l wherein each A is selected from the group consisting of P, As, N, O, S, Sb, Se andTe. 3. The composition of Claim 1 further comprising stannous ion. 4. The composition of Claim 1 having a pH less than 3.0. 5. The composition of Claim 1 having a pH less than 2.2. 6. The composition of Claim 1 in sterile, lyophilized form in a pre sterilized, sealed container. 7. The composition of Claim 1 wherein said target seeking ligand has the formulasEMI34.1 wherein M and M are arsenic, phosphorus, nitrogen, sulfur, oxygen, selenium, tellurium, or any combination of them R and R are independently hydrogen, an alkyl group having from 1 to about 6 carbon atoms, or an aryl group and n and n are independently the integer 1 or 2. 8. The composition of Claim 1 wherein said target seeking ligand has the formula R n M CX 2CX2MRn wherein M and M are arsenic, phosphorus, nitrogen, sulfur, oxygen, selenium, tellurium, or any combination of them R and R are independently hydrogen, an alkyl group having from 1 to about 6 carbon atoms, or an aryl group X and X are independently selected from hydrogen, halide, or substituted or unsubstituted lower alkyl groups having 1 to about 6 carbon atoms and n and n are independently the integer 1 or 2. 9. The composition of Claim 1 wherein said target seeking ligand has the formula EMI35.1 wherein M, M and N1 are independently selected from arsenic, phosphorous, nitrogen, sulfur oxygen, selenium, and tellurium R, R and R are independently selected from hydrogen, halide, an alkyl group having 1 to about 6 carbon atoms, or an aryl group n is 0 or 1 and n and n1 are independently the integer 0, 1 or 2. 10. The composition of Claim 1 wherein said target seeking ligand has the formula EMI35.2 wherein A is P or Ast and each R is independently H, a lower alkyl group having from 1 to about 6 carbon atoms, or phenyl. 11. The composition of Claim 1 wherein said target seeking ligand has the formula EMI36.1 12. The composition of Claim 1 wherein said target seeking ligand has the formulaEMI36.2 wherein R is H or a lower alkyl group having 1 to about 6 carbon atoms. 13. A method for making a complex labelled with Tc 99m for radioscintigraphic imaging, said method comprising admixing 99mTc pertechnetate and the composition of Claim 1 and placing the resulting admixture in a constant temperature water bath for a period of time sufficient to form such labelled complex. 14. The composition of Claim 1 wherein said target seeking ligand is tetradentate ligand having neutral donor atoms selected from nitrogen and sulfur atoms. 15. The composition of Claim 1 wherein said target seeking ligand is a compound having the EMI37.1 16. The composition of Claim 15 wherein each neutral donor atom is selected from nitrogen and sulfur. 17. The composition of Claim 1 wherein said target seeking ligand is a bisamido, bisthiol compound. 18. The composition of Claim 1 wherein said target seeking ligand has the formula EMI37.2 19. The composition of Clam 1 wherein said target seeking ligand has the formula EMI38.1 20. The composition of Claim 1 wherein said target seeking ligand has the formula EMI38.2 21. The composition of Claim 1 wherein said target seeking ligand has the formula EMI38.3 22. The composition of Claim 1 wherein said target seeking ligand has the formula EMI39.1 23. The composition of Claim 1 wherein said target seeking ligand has the formula EMI39.2 24. The composition of Claim 1 wherein said target seeking ligand has the formula EMI39.3 25. The composition of Claim 1 wherein said target seeking ligand is an isonitrile ligand. 26. The composition of Claim l wherein said target seeking ligand has the formula CN yR where x is an integer from 1 to 8.

## Description
SOLUBLE COPPER SALT CONTAINING COMPOSITIONS USEFUL FOR FORMING TECNETIUM LAPLLED RADIODIAGNOSTIC AGENTS Afield of the Tnvention The present invention relates to compositions for making technetium labelled radiodiagnostic agents and, in particular, to soluble copper salt containing compositions for reducing technetium or accelerating the reduction of technetium for labelling such radiodiagnostic agents, kits for preparing such 99mTc labelled radiodiagnostic agents with technetium, and methods for labelling such radiodiagnostic agents with technetium. background of the Invention Various complexes of monodentate and bidentate ligands with technetium have been made and studied. These complexes have been made in many cases for use in studies to determine the various oxidation states of technetium and for other research regarding the structure of such complexes and metal coordination chemistry. Such studies have been reported in, for instance, Chemistry and Industry, pp. 347 8 March 26, 1960 J. Tnorq, NucL.Chem., Vol. 28, pp 2293 96 1966 Aust. J. Chem., 23, pp 453 61 1970 Inorganic Chem., Vol. 16, No. 5, pp. 1041 48 1977 J. Tnorg.Nuci. Chem., Vol. 39, pp. 1090 92 1977 and JCS. flaiton, pp. 125 30 1976 . In recent years many compounds or ligands have been labelled with technetium for use as radiodiagnostic agents. For instance, in a presentation to the AmericanPharmaceutical Association, E.A. Deutsch disclosed that certain complexes of DIARS, i.e.EMI2.1 and Tc 99m, and certain complexes of DMPE, i.e. CH3 2 PCE2CE2P CH3 2, and Tc 99m may be useful as radiodiagnostic agents for myocardial or hepatobiliary imaging. t99mTC DMPE 2C12 and t99mTc DIARS 2 Br2 1 were prepared byDeutsch by heating in an open flask a reaction mixture containing the appropriate hydrogen halide in aqueous alcohol solution, 99mTc sodium pertechnetate, and ortho phenylenebis dimethylarsine , i.e DIARS, or bis 1,2 dimethylphosphino ethane, i.e. DMPE. The reaction was reported to take about 30 minutes. The labelled complex was then purified by chromatographic methods involving ion exchange columns. U.S. Patent No. 4,452,774 describes coordination complexes of an isonitrile ligand with various radionuclides including technetium. Representative isonitrile complexes include those represented by the formula LA CN xR yBzB tin in which A is a radionuclide selected from radioactive isotopes of Tc, Ru, Co, Pt, Fe, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Pd, Nb, and Ta, for example, 99mTc, 99Tc, 97Ru, 51cr, 57Co, 188Re and l91os CN xR is a monodentate or polydentate isonitrile ligand bonded to the radionuclide through the carbon atom of the CN group R is an organic radical B and B are independently selected from other ligands well known to those skilled in the art that result in isonitrile complexes, including solvents such as water, chloro and bromo groups, and ligands comprising one or more neutral donor atoms capable of forming bonds with said radionuclide x and y are each independently, integers from 1 to 8 z and z are each independently 0 or an integer from 1 to 7 with the proviso that xy z z is less than or equal to 8 and n indicates the charge of the complex and can be O neutral , or a positive or negative integer the value of which depends upon the vaience state of A, and the charges on R, B and B . Any desired counter ion can be present as required by the charge on the complex with the proviso that such counterion must be pharmaceutically acceptable if the complex is to be used in vivo. Particularly useful isonitrile ligands are the homoleptic six coordinate hexakis cationic complexes having the formula rA CNR 6J in which A is a monovalent radionuclide such as technetium, CNR is a monodentate isonitrile ligand, and R is an organic radical. A suitable counterion is also present. A bisamide bisthiol N2S2 chelate that forms a complex with reduced technetium, E99mTcO ema 1, was described as a potential renal agent by Davison et al . Nucl, Med. 20 60 , 641 lay79 . it was subsequently shown to be excreted into both the urine and bile in a chemically unchanged form, Jones et al 3. Null. Med. 23 9 , 801 1982 , thus fulfilling one of the requirements for a renal radiodiagnostic agent. Such ligands are typically labelled with technetium by combining the ligand in solution with pertechnetate and a reducing agent. Generally, tin or stannous ion is used as the reducing agent for the technetium. However, other reducing agents have been utilized for this purpose. U.S. 4r314,986 describes a method of reducing the pertechnetate in Tic04 comprises mixing together an aqueous solution of pertechnetate, e.g. the eluent from a technetium generator, metallic tin or an alloy thereof as a reducing agent for the pertechnetate, and a soluble salt of a metal below tin in the electrochemical series, e.g. copper, as an activator for the tin reducing agent. A complexing agent for the reduced technetium or a colloid stabilizer may also be included. The pH is preferably 3 to 12. European Patent Application Publication No. 0 063 946 describes a complex of technetium 99m with an acid having the formula HOOC CH2 X CH2 COOH, where X is sulphur or selenium, having glomerular filtration and tubular secretSbd tbbt ieE which make it useful in the diagnostic technique of renography to give a dynamic representation of the functioning of the kidneys.The complex may be prepared a by reducing Tic04 with a Sn reducing agent in the presence of Cu and of the acid, or b by reducing Tic04 with a tin metal reducing agent in the presence of a cupric salt and of the acid. In both U.S. 3,314,986 and European Publication No. 0 063 946, the tin or stannous salt is the reducing agent and the cuprous or cupric ion is used as a catalyst for the tin or stannous salt. Some target seeking ligands are not labelled as easily or efficiently with technetium using conventional labelling techniques. For instance, to obtain high yields of technetium labelled DMPE, temperatures of about 1300C are required. Thus, new techniques for labelling ligands with technetium that facilitate or accelerate the labelling process are desirable.Summary of the rnvention The present invention provides a method and compositions for preparing technetium complexes for use as radiodiagnostic agents. The compositions of this invention comprise and admixture of a a soluble copper salt and b a target seeking ligand L , or aqueous salt thereof, having the following structure EMI6.1 wherein i is an integer from 1 to 6t R, R1, R2, R3, R4, R5 and R6 are each independently selected from hydrogen or substituted or unsubstituted alkyl, aryl, alkylaryl, arylalkyl, monocycloalkyl, polycycloalkyl, heterocyclic and carbocyclic groups, and R plus Ri may be taken together to form a cyclic compound or separately to form a linear compound yl, y2, y3, y4, y5 and y6 are independently selected from substituted or unsubstituted alkyl, aryl, alkylaryl, arylalkyl, monocycloalkyl, polycycloalkyl, heterocyclic and carbocyclic groups A1, A2, A3, A4, A5 and A6 are the same or different donor atoms, each having a free electron pair available for complexing with Tc 99m or Tc 99 and klr k2r k3, k4, k5 and k6 are each independently zero or one or EMI7.1 or EMI7.2 wherein R, R , R and R are independently selected from hydrogen or substituted or unsubstituted alkyl, aryl, alkylaryl, arylalkyl, monocylcloalkyl, polycycloalkyl, heterocyclic and carbocyclic groups A, A , A and A are independently selected from the group of donor atoms having a pair of electrons available for complexing with Tc 99m or Tc 99 B is an atom selected from the group of donor atoms having a pair of electrons available for complexing with Tc 99m orTc 99 boron, or from the elements listed in Group IV A of the periodic table i.e.C, Si, Ge, Sn, and Pub m is 0 or 1 and n , n and n are independently the integer 1 or 2. In a preferred embodiment of this invention, the composition and kit are useful for preparing technetium labelled complexes in yield high enough to be useful for radiodiagnostic agents using ordinary water baths for heating and without the need for purification. The compositions of this invention comprising the soluble copper salt, preferably as the cupric ion, and target seeking ligand are preferably supplied as a kit as lyophilized solids in a pre sterilized vial. Useful cationic technetium complexes arefprepared in accord with this invention, for example, by adding 9imTc pertechnetate solution to the vial and heating in a water bath to obtain high yields of the desired complexes. The R s and Y s in formulas I, II and III are preferably alkyl radicals having 1 to about 6 carbon atoms such as methyl, ethyl, etc., and the like, and aryl radicals such as benzyl, phenyl, etc., and the like. The complexes formed from compositions and kits of this invention, when radiolabelled with technetium are useful for radiodiagnostic tests, for example, in connection with myocardial and hepatobiliary tissues.Detailed Description of the Invention The compositions and kits of the present invention can be prepared from a wide variety of monodentate and polydentate target seeking ligands. Typical examples of such ligands include, for instance, aryl compounds having arsenic, phosphorus, nitrogen, sulfur, oxygen, selenium, tellurium, or any combination of them, substituted ortho to each other. For example, o phenylene compounds having the structure EMI9.1 in which M and M are arsenic, phosphorus, nitrogen, sulfur, oxygen, selenium, tellurium, or any combination of them, n and n are independently 1 or 2 depending upon the particular donor atom used for M and , and R and R are independently hydrogen, or an organic group, preferably an alkyl group having 1 to 6 carbon atoms, an aryl group such as phenyl, or the like, and substituted such groups.Additional examples of suitable target seeking ligands include bidentate cis tetraethylene ligands of the formula ROn,M GX 2CX2 MRn V in which M, M , R, and R are as defined above, n and n are independently 1 or 2 depending upon the particular donor atom used for M and M , and X and X are independently selected from hydrogen, halide, or substituted or unsubstituted lower alkyl groups having 1 to about 6 carbon atoms.Further examples of suitable target seeking ligands include those having the formula EMI10.1 where M, M , R, and R , are as defined above, Mw is independently selected from arsenic, phosphorous, nitrogen, sulfur, oxygen, selenium, and tellurium, n is O or 1, n and nZ are independently selected from 0, 1 or 2, and Rw is independently selected from hydrogen, halide or an organic radical, preferably an alkyl radical having 1 to about 6 carbon atoms, an aryl radical such as phenyl, or the like, and substituted such groups. Particularly preferred ligands for the practice of this invention are the bis dialkylphosphinoethanes, their substituted derivatives, and similar ligands, including, for example, 1,2 bis dimethylphosphino ethane, 1,2 bis di trifluoromethyl phosphino ethane, 1 ,2 bis dimethylphosphino l ,l difluoroethane, 1 ,2 bis dimethylphosphino 1 fluoroethane, 1 ,2 bis Cdimethylphosphino propane, 1,2 bis di trifluoromethyl phosphino l,l,2,2 tetrafluoroethane, 1,2 bis di trifluoromethyl phosphino propane, 2 ,3 bis di trifluoromethyl phosphino butane, 1 ,2 bis di trifluoromethyl phosphino butane, 1, 3 bis dimethylphosphino butane, 1 ,3 bis dimethylphosphino propane, 1,3 bis di trifluoromethyl phosphino propane, lt2 bistdimethylphosphino lfl dichloro 2t2 difluoroethanet and other similar co mpounds wherein the phosphorus is replaced by nitrogen, arsenic, sulfur, oxygen, selenium, tellurium, or any other atom having a free electron pair, and the like. Other useful target seeking ligands include the alkylaminobis difluorophosphine , i.e., RN PF2 2, ligands and the liKe where R is an organic group, preferably an alkyl group having 1 to about 6 carbon atoms, an aryl group as phenyl, or the like, and substituted such groups and the o phenylene compounds such as, for example, orthophenylenebis diarsine , orthophenylenebis dimethylarsine , orthophenylenebis diamine , orthophenylenebis dimethylamine , orthophenylenebis diphosphine , orthophenylenebis dimethylphosphine , and the like. Additional target seeking ligands suitable for use in the present invention are those described by Nozzo et al., in J. Amgr, Chem. Soc.. lal, p. 3683 1979 and by Wilson et al., , Amer. Chem. Soc.. LQQ, p. 2269 1978 , which are hereby incorporated by reference. Additional preferred target seeking ligands useful in the practice of this invention include isonitrile ligands as described above. As aforementioned such isonitrile libands CN x R, where x is an integer from 1 to 8, are any monude tate or polydentate isonitrile ligands which are capable of complexing the metal atom through the carbon atom of the CN group. In the isonitrile ligand, R is an organic radical as defined for formulaI above that can have additional neutral donor atoms capable of forming coordinate bonds with technetium. Further preferred target seeking ligands useful in the practice of this invention include tetradentate ligands or salts of such ligands having the general formula EMI12.1 where Al, A2, A3 and A4 are independently neutral donor atoms having a pair of electrons available for complexing with technetium, preferably nitrogen or sulfur atoms and R1, R2, R3,R4 and R5 are organic radicals selected from substituted and unsubstituted alkyl and aryl groups, or hydrogen where applicable. Some neutral donor atoms may require additional groups to satisfy their coordinate bond requirements not shown in formula IV above.Examples of such tetradentate ligands include, for example,EMI13.1 and bisamido. bisthio liaands such asEMI13.2 EMI14.1 and similar such ligands, where the R s are independently selected from hydrogen, and substituted or unsubstituted lower altyl groups, where the R s attached to thiol atoms are hydrogen or known thiol protecting groups. The term slower alkyl when used in this application designates aliphatic saturated branched or straight chain hydrocarbon monovalent substituents containing from 1 to 4 carbon atoms such as methyl, ethyl, isopropyl, n propyl, n butyl, t butyl, etc. The term substituted lower alkyl when used herein includes alkyl groups substituted with halide, hydroxy, carboxylic acid, or carboxamide groups, etc. such as, for example, CB2OH, CH2CH2COOB, CH2CONH2, OCH2CH2OH, OCH2COOH, OCH2CH2CONH2, etc. Some examples of thiol protective groups are lower alkylaminocarbonyl such as ethylaminocarbonyl, lower al kanoylaminomethyl, a roylaminomethyl, t butyl, acetamidomethyl, arylmethyl such as triphenylmethyl trityl and diphenylmethyl, aroyl such as benzoyl, aryloxycarbonyl such as phenoxycarbonyl, arylloweralkoxylcarbonyl, preferably arylmethoxycarbonyl such as benzyloxycarbonyl, and lower alkoxycarbonyl such as t butoxycarbonyl. Preferred thiol protecting groups include trityl, t butyl, diphenylmethyl, acetamidomethyl and benzoyl. Examples of such bisamido, bisthio compounds include N 2 mercaptoethyl 2 mercaptoacetylOglycinamide N 12 benzOylthio ethyl 2 benzoylthSoacetyl glycinamide N 12 tacetamidomethylthio ethyll 2 acetamidomethylthioacetyl glycinamide 2 mercaptoacetyl glycyl cysteine methyl ester 2 benzoylthioacetyl glycyl S benzoyl cysteine methyl ester E2 acetamidomethylthio acetyljglycyl S acetamidomethyl cysteine methyl ester 2 mercaptoacetyl glycyl cysteinet 2 benzoylthioacetyl glycyl S benzoyl cysteine 12 acetamidomethylthio acetyllglycyl tS acetamidomethyl cysteine 2 mercaptoacetyl glycyl cysteinyl glycine methyl ester 2 benzoylthioacetyl glycyl S benzoyl cysteinyl glycine methyl estert t2 tacetznidomethylthio acetyllglycyl S acetamidomethyl cysteinyl glycine methyl estert N t2 mercaptoethyl N l carbomethoxy 2 mercaptoethyl oxamide N t2 benzoylthio ethyll N carbomethyoxy 2 benzoylthio ethylloxamidesN 2 acetamidomethylthioNethyll N tl carbomethoxy 2 tacet amidomethylthio ethyli oxamide N,N bis 2 mercaptoethyl oxamide N,N bis 2 benzoylthio ethylioxamide N,N bisl2 acetamidomethylthio ethylloxamide l R,R N,N bis l carbomethoxy 2 mercaptoethyl oxamide tR,R N,N biE l carbomethoxy 2 benzoylthio ethylloxamide and R, N,N bistl carbomethoxy 2 acetamidomethylthio ethyll oxamide. The organic radicals i.e. R groups referred to in the structual formulas herein can be aliphatic or aromatic and may be substituted with a variety of groups which may or may not I be charged. Among the aromatic R groups which may be present are phenyl, tolyl, xylyl, naphthyl, diphenyl and substituted aromatic groups containing such substitutents as halo, e.g., chloro, bromo, iodo or fluorot hydroxy, nitro, alkyl, alkoxy, etc. among the aliphatic R groups which may be present are alkyl, preferably containing 1 to 20 carbon atoms, such as methyl, ethyl, n pro l isopropyl, n butyl, isobutyl, n hexyl, 2 ethylhexyl, dodecyl, stearyl, etc.Substituent groups may also be present in the aliphatic groups, including among others the same substituent groups as those listed above for aromatic groups. In general, it is desirable to achieve the characteristics of the labelled complex without the need for substituent groups. Thus, it is preferred for the sake of simplicity to employ unsubstituted hydrocarbon groups as the R groups whenever possible. However, the lipophilic characteristics of the complex can be further varied by varying the R groups to adapt the complex for labelling selected materials, for membrane transport such as for the blood brain barrier, or for imaging selected organs and dynamic processes related to their function. Any donor element can be used in the target seeking ligand in accord with this invention provided that it is a neutral donor atom having a free electron pair available for accepting a proton to provide a charged ligand and further provided that it has the capability of complexing with technetium Tc 99 or Tc 99m . Suitable such elements include, for instance, phosphorous P , arsenic As , nitrogen N , oxygen 0 , sulfur S , antimony Sb , selenium Se , tellurium Te , and the like. Although technetium complexes prepared in accord with 1 invention can be neutral, or positively or negatively t ged, the class of lipophilic cationic complexes is presently w 3ferred. Preferably, the complexes prepared in accord with this invention are kinetically inert, and hence stable products.however, the complexes need only be sufficiently stable for the intended use. Any desired counter ion may also be present in the Ã§omposition, such as , in the case of cationic complexes, chloride, fluoride, bromide, iodide, hydroxide, sulfate or bisulfate, dihydrogen phosphate, fluoroborate, hexafluorophosphate, etc. The copper can be supplied by any soluble copper salt having a pharmaceutically acceptable anion, but preferably is in the form of a cupric salt. The sulfate and chloride salts are preferred. The compositions of this invention are useful for preparing radiodiagnostic agents wherein the target seeking ligand is labelled with technetium. Labelling is accomplished by mixing a suitable quantity of 99mTc pertechnetate in solution with the cupric ion and target seeking ligand, and heating the admixture for a suitable length of time at a temperature attainable with a constant temperature water bath. Preferably, the heating step is performed at 100 C for thirty minutes or less. An aqueous physiological saline solution is typically the solution of choice for labelling the target seeking ligand because it is readily administered to the patiY, During labelling the pH of the solution is desirably less than 3. Preferably, the pH is less than 2.2. It has been found that the addition of stannous ion to the composition can increase the yield of technetium complex up to about 10 . In addition, the presence of ascorbic acid in the composition significantly increases the yield of the technetium complex at higher pH levels. The compositions of this invention are preferably contained in a kit, such as a presterilized vial. The presterilized vial, such as a glass vial, containing the compositions of this invention is ready for use for preparing cationic technetium complexes for radiodiagnostic use. More preferably, the compositions are lyophilized in such kits to increase storage stability of the compositions. In such lyophilized kits, the target seeking ligand is generally present as a water soluble acid salt of the ligand. The lyophilized kits are used by reconsituting with a suitable quantity of 99mTc pertechnetate in saline solution. T reconstituted compositions are then placed in a constant temperature water bath for a sufficient time to form labelled technetium complexes with the target seeking ligand. Preferably, the reaction time is about 30 minutes or less at a temperature of about lOO0C. In order to obtain high quality images the yield of radioactive labelled cationic technetium complex should m ably be greater than 70 after recorstltnting the y lized mixture and labelling. Lower yields will result in poser image quality and undesirable purification steps will be z uired to produce high quality images. This invention will be further illustrated by the examples that follow tDatation of I.l Bfs dimethvlDhosDhina ethane bis hisulfate. 2 . nEPEw22 2Rs0 4 or DMPR 292fiQ4 Dissolve 470 mg of DMPE in 10 ml of ethanol in a 50 ml round bottomed flask maintained under a nitrogen atmosphere. Erom a glass syringe, add, with stirring, 0.34 ml of concentrated sulfuric acid. After 10 minutes, filter the precipitate and recrystallize it from 10 ml. of methanol. Filter and dry under vacuum. 920 mg of a crystalline solid is obtained, which melts at 135 136.50C, Structure and purity of the compound was confirmed by its infra red and nuclear magnetic resonance spectra and elemental analysis. Comparative example A Dissolve 50 mg of DMPE 2H2S04 in about 35 mls of deoxygenated physiological saline. With stirring adjust the pH to 1.0 with 3N H2S04. Add deoxygenated saline drop wise, to a solution weight of 40 grams. Dispense 0.8 mls of the solution into each of several 10 cc vials that bad ben sealed and purged , with N2. Each vial is called a wkitw herein. Dispense into each kit i.e. vial 0.2 mls of physiological saline containing approximately 25 mCi of 99mTc04 . Place the vials in a common water bath, preheated and a constant boil heat for 15 minutes. TLC analysis shows a yield of 2 5 of 99mTcC12DMPEI . r Comparative example B Conventional Stannous Reducing Agent Dissolve 125 mg of DMPE2H2SO4 and 12.5 mg of SnC12B2H20 into about 95 mls of physiological saline. With stirring adjust the pH to 1.0 with 3N H2SO4. Add deoxygenated saline drop wise until a solution weight of 100 grams. Dispense 0.8 mls of the solution into each of several 10 cc vials as in Example A above. Dispense into each kit 0.2 mls of physiological saline containing approximately 25 mCi of 99mTcO4. Place the vials in a common hot water bath, preheated and on a constant boil, heat for 15 minutes. TLC analysis shows a yield of about 10 15 of 99mTcCl2DMPE0 . Example 1 Dissolve 125 mg of DMPE 2B2S04 and 12.5 mg of CuS04B5H20 into about 95 mls of saline. With stirring adjust the pH to 1.0 with 3N H2S04. Add deoxygenated saline drop wise until a solution weight of 100 grams. Dispense 0.8 mls of the solution into each of several 10 cc vials that had been sealed with a teflon coated stopper, crimp sealed and purged with K2 for several minutes . Dispense into each kit 0.2 mls of physiological saline containing approximately 25 mCi of 99mac04 . Place with vials in a common hot water bath, preheated and on a constant boil, heat for 15 minutes. TLC analysis shows a yield of about 95 of 99mTcCl2DMPEj . example 2 Dissolve 6.25 mg of SnCl22H2O in 1.0 mls of 3N B2S04. Add 45 mls of deoxygenated physiological saline 0.15 Molar .With stirring add 62.5 mg of DMPE2H2SO4 and 6.25 mg of CuS04o5H20. Adjust the pH to 1.0 with 3N H2SO4. Add deoxygenated saline drop wise to a solution weight of 50 grams. Dispense 0.8 mls of the solution into each of several 10 cc vials, that had been sealed with a teflon coated stopper, crimp sealed and purged with N2 for several minutes. Dispense into each kit 0.2 mls of physiological saline containing approximately 25 mCi of 99mTcO4 . Place the vials in a common hot water bath, preheated and on a constant boil, heat for 15 minutes. TLC analysis shows a yield of 95 to 1008 of t99mTcC12DMPEl . Example 3 Dissolve 4.0 mg CuS04e5H20, 40.0 mg DMPE 2E2S04, 4.0 mg SnCl 2H20 and 800 mg Mannitol in about 35 mls of low oxygen saline. With stirring adjust the pH to 1.0 with 3N B2S04. Add low oxygen saline drop wise until a solution weight of 40 grams.Dispense 1.0 mls of this solution into each of several 10 cc vials. Lyophilize these vials and stopper under N2.Reconstitute each vial with 1.0 mls of physiological saline containing about 25 mCi of 99mTc04 . Beat in a water bath for 15 minutes at 1000C. Thin layer chromatography TLC analysis show yields consistently greater than 95 of l99mTcC12DMPEl . Example 4 Dissolve 6.3 mgtof SnC122B20 in 1.0 mls of 3N H2S04,Add 45 mls of deoxygenated physiological saline 0.15 M . With stirring add 625.0 mg of DMPE H2S04, 6.3 mg of CuS04 5H20 and 625 mg ascorbic acid. Adjust the pH to 1.0 with 3N H2S04, Add deoxygenated saline drop wise, to a solution weight of 50 grams.Dispense 0.8 mls of this solution into each of several 10 cc vials that had been sealed with a teflon coated stopper, crimp sealed and purged with N2 for several minutes . Dispense into each kit 0.2 mls of physiological saline containing approximately 25 mCi of 99mTc04 . Place the vials in a common hot waterbath, preheated and on a constant boil, heat for 15 minutes. TLC analysis shows a yield of 1008 of f99mTcC12DMPEl .Example 5 Dissolve 3.2 mg of SnC12 2H20, 3.2 mg of CuS04 5B20 and 31.25 mg DMPE2B2S04 in about 23 mls of degassed saline. With stirring 3.2 grams of ascorbic acid is added. The pH iz theii adjusted to 1.8 with 3N NaOH. Add deoxygenated saline drop wise to a solution weight of 25 grams. Dispense several 0.8 ml aliquots into 10 cc vials that are sealed and purged with N2.Label kits as performed in previous examples. TLC analysis shows greater than 95 yield of 99mTcCl2DMPEi . Exaniple6 Dissolve 6.3 mg of SnC12e2H20 in 1.0 mls of 3N H2S04.Add 45 mIsof deoxygenated physiological saline 0.15 Molar .With stirring add 62.5 mg of DMPE 2B2S04, 6.3 mg of CuS04 5N20 and 625.0 mg of tartaric acid. Adjust the pH to 1.0 with 3N H2S04. Add deoxygenated saline drop wise to a solution weight of 50 grams. Dispense 0.8 mls of the solution into each of several 10 cc vials that had been treated as in previous examples . Dispense into each kit 0.2 mls of physiological saline containing approximately 25 mCi of 99mTcO4. Place the vials in a common water bath, preheated and on a constant boil, heat for 15 minutes. TLC analysis shows a yield of 100 of t99mTcC12DPEl . Examples 7 73 For each of the following examples, each formulation was in a 150 ml flat bottom flask. To the flask was added the required amount of each solid, then an appropriate volume of degassed saline was added to dissolve the solids and bring the total volume to near the final volume, with stirring nitrogen gas bubbled through the solution at steady rate during the preparation of bulk formulations. The pH was then adjusted with either 3N B2S04 or 2N NaOB to the desired pH. Volume of the bulk solution was finally adjusted gravimetrically by addition of saline. Several 0.8 ml aliquots of the bulk solution were dispensed into 10 cc vials, crimp sealed and flushed with nitrogen. NOTE This volume was chosen for the kit so that addition of 0.2 ml of Tcggenerator eluate would result in a 1.0 ml final volume of solution. The bulk solution was made more concentrated to compensate for this dilution.i After reconstitution with 0.2 ml 99mTc04 eluate, each kit or vial was heated in a boiling water bath 1000C for 15 minutes unless indicated otherwise. . In Examples 7 16 the amount of DMPE 2H2So4 was varied as indicated. Otherwise, each kit or vial contained 100 ug CuS04 5H20 and 100 ug SnC12 2H20 at a pH of 1.0. example Amount of flMPE Yle0d of TcCl 7 1,000 ug 100 10 8 500 ug 100 94 9 350 ug 91.9 10 346 ug 97.3 100 11 315 ug 83.7 83.2 12 275 ug 94.1 93.2 13 250 ug 84.0 86.0 14 208 ug 9.0 0 15 173 ug 0 0 16 100 ug 0 0 Two values shown indicates that the measurement was repeated. B. In Example 17 22 the amount of DMPE 2R2go4 was varied as indicated. Otherwise, each kit or vial contained 150 ug CuS04R5H20 and 100 ug SuC12R2R20 at a pH of 1.0.Example Amount of DMPE t Yield of tgcC12 dmpe 21 17 1,000 ug 100 100 90,8 94.2 18 467 ug 99.2 99.2 19 415 ug 100 100 93.1 95.5 20 390 ug 99.3 98.1 93.9 99.1 21 380 ug 100 97.6 96.3 99.2 22 350 ug 0 0Values in parenthesis indicate that a second vial was labelled and measured. C. In Examples 23 28 the amount of CuS04 5H20 was varied as indicated. Otherwise, each kit pr vial contained 1000 ug DMPEe2H2S04 and 100 ug SnC12.2H2O at a pE of 1.0. Amount of Yield of Example Cu SH20 Tc C1Zdmoelc, SO 23 1,000 ug 0 0 24 300 ug 100 100 100 98.9 25 200 ug 100 100 26 150 ug 100 100 27 100 ug 100 100 28 50 ug 95.1 86.2 D. In the following Examples 29 31, the reaction time was shortned to 5 minutes, Otherwisel the vials were prepared was shortened to 5 minutes. Otherwise, the vials were prepared as for Examples 23 28 above. Amount of Reaction Yield of Example CuSO42.5H2O Time 99mTcCl2 dmpe 2 29 50 ug 5 min. 79.0 19.4 30 100 ug 5 min. 85.7 89.3 31 150 ug 5 min. 90.8 94.2 E. In the following Examples 32 38 the amount of CuSO4 5H2O and SnCl2.2H2O were varied as indicated. Otherwise, each vial or kit contained 1000 ug of DMPE 2H2SO4 at a pE of 1.0. Amount of Amount of t Yield of Example CuSO4.5H2O 0 z 99mTcCl2 dmpe 2 33 72 2400 91.8 90.3 34 72 4000 97.1 93.2 35 100 100 100 100 36 100 1000 98.8 100 37 100 2500 97.2 97.1 38 160 2400 100 100 39 0 100 21.3 20.6 40 100 0 95.8 95.9 41 200 0 94.3 94.8 42 300 0 96.3 96.7 F. In Examples 43 52 the pH and the amount ofCUSO4.5H2O and SnC12 Hs0 were varied as indicated. Otherwise, each vial or kit contained 1000 ug DMPE 2H2SO4. Yield of Amount of Amount of 99mTcCl2 Example CuSO4.5H2O SnCl2.2H2O 0.6 96.3 43 pR dmpe21 44 170 3,000 1.0 98.3 98.8 45 170 3,000 1.4 95.0 95.4 46 170 3,000 1.9 15.4 16.1 47 170 3,000 2.4 16.8 15.7 48 100 100 1.0 100 98.6 49 100 100 1.2 67.4 69.1 50 100 100 1.4 41.6 42.4 51 100 100 1.6 35.9 39.0 52 100 100 1.8 30.7 33.1 G. In Examples 53 60 the pH is varied as indicated.Otherwise, each vial or kit contains 1000 ug DMPEs2H2SO4, 100 ugCuSO4 5H2O, 100 ug SnC12 2H20 and 100 mg ascorbic acid. Yield ofExamples pH 99mTcCl2 dmpe 2 53 1.2 100 100 54 1.4 100 100 55 1.6 88.9 90.5 56 1.8 96.1 100 57 2.0 97.2 90.7 58 2.2 85.1 82.5 59 2.4 74.8 83.1 60 2.6 69.3 74.1 B. In Examples 61 68 the time of reaction, the pH and the amount of CuSO405H2O and SnC12 2HZO were varied as indicated.Otherwise, each vial contained 1000 ug DMPE 2H2SO4 and 20 mg mannitol. Yield of Amount of Amount of Reaction 99mTcCl2 Example CuSO4 SnCl2 2H2O pH Time dmpe2 61 100 ug 100 ug 1.2 15 73.0 0.9 62 100 ug 100 ug 1.2 30 96.6 87.9 63 150 ug 150 ug 1.0 15 96.1 100 64 150 ug 150 ug 1.0 30 100 100 65 150 ug 150 ug 1.2 15 79.6 80.0 66 150 ug 150 ug 1.2 30 95.5 95.2 67 150 ug 150 ug 1.4 15 41.5 45.2 68 150 ug 150 ug 1.4 30 67.0 66.5 I. In Examples 69 73 various additives were added in the amounts indicated. Otherwise, each vial or kit contained 1000 ug DMPE 2H2SO4, 100 ug CuSO4 5B2O, and 100 ug SnC12 2H20 at a pH of 1,0. Yield ofExample Additive 9mTcCl2 dmpe 2 69 10 mg Mannitol 100.98.4 70 20 mg Mannitol 96.1 100 71 100 mg Mannitol 100 100 72 10 mg Ascorbic 100 100 Acid 73 10 mg Tartaric 100 100 Acid Examples 74 77 In each of Examples 74 77, each formulation was prepared as in Examples 7 73 above. The particular target seeking ligand was varied as indicated. Otherwise each vial or kit contained 1 mg target seeking ligand, 300 ug CuSO4.5H2O and 100 ug SnC12 2H2O at a pH of 1.0. Target Seeking 89 Yield ofExample Liaand L 99mTcCl2 L 2 74 DMPP 73.8 76.5 75 DIMARS 93.1 89.0 76 DIARS 72.8 83.2 77 ASP 96.4 95.2 DMPP bis 1,3 dimethylphosphino propane DIMARS bis 1,2 dimethylarsino ethaneASP l dimethylphosphino 3 dimethylarsino propane The preferred ratios of materials or the optimum amounts of each target seeking ligand, copper salt and other materials and parameters can be readily determined for particular system in a manner similar to that illustrated above in Examples 7 73. For the ligand DMPE, it appears that a molar ratio of at least 1.8DMPE to cupric ion is required to obtain a labelled complex under the conditions investigated. The invention has been described in detail, including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.